# Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine

> **NCT04531072** · PHASE4 · COMPLETED · sponsor: **Fogarty International Center of the National Institute of Health** · enrollment: 20 (actual)

## Conditions studied

- Drug Interaction

## Interventions

- **DRUG:** Artemether-lumefantrine
- **DRUG:** Atazanavir-ritonavir 300/100 mg

## Key facts

- **NCT ID:** NCT04531072
- **Lead sponsor:** Fogarty International Center of the National Institute of Health
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-18
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-08-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531072, "Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04531072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*